NeuroPace, Inc. (NPCE)
| Market Cap | 573.08M |
| Revenue (ttm) | 99.99M |
| Net Income (ttm) | -21.47M |
| Shares Out | 33.95M |
| EPS (ttm) | -0.66 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 144,300 |
| Open | 17.27 |
| Previous Close | 17.25 |
| Day's Range | 16.86 - 17.45 |
| 52-Week Range | 7.56 - 18.98 |
| Beta | 1.88 |
| Analysts | Strong Buy |
| Price Target | 18.33 (+8.59%) |
| Earnings Date | May 8, 2026 |
About NPCE
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programmin... [Read more]
Financial Performance
In 2025, NeuroPace's revenue was $99.99 million, an increase of 25.13% compared to the previous year's $79.91 million. Losses were -$21.47 million, -20.91% less than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for NPCE stock is "Strong Buy." The 12-month stock price target is $18.33, which is an increase of 8.59% from the latest price.
News
NeuroPace Highlights Expanding Clinical Evidence Leadership with Published 3-Year Post-Approval Study (PAS) Results in Neurology and NAUTILUS Presentation at AAN 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with drug resistant epilepsy, today announced a majo...
NeuroPace Transcript: 25th Annual Needham Virtual Healthcare Conference
The company reported strong 2025 growth, reaching $100 million in revenue and expanding its patient base. Key initiatives include FDA submission for IGE indication, AI-driven product enhancements, and a broadened sales force. 2026 is expected to be transformational, with further market and clinical expansion.
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Transcript: Leerink Global Healthcare Conference 2026
Growth is driven by increased adoption at epilepsy centers, improved referral management, and commercial investments. NAUTILUS trial data support a major new indication, with FDA review ongoing and a large untapped patient population. Commercial rollout will be phased as payer coverage expands.
NeuroPace to Present at the Leerink Global Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Earnings Call Transcript: Q4 2025
Q4 and full-year 2025 saw strong revenue growth, improved margins, and positive adjusted EBITDA, driven by RNS adoption and disciplined execution. 2026 guidance projects continued double-digit growth, with new AI tools and potential IGE indication expansion as key catalysts.
NeuroPace Reports Fourth Quarter and Full Year 2025 Financial Results and Reiterates 2026 Outlook
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...
NeuroPace to Report Fourth Quarter 2025 Financial Results on March 3, 2026
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ...
NeuroPace Transcript: 44th Annual J.P. Morgan Healthcare Conference
Strong 2025 results included $100 million in revenue and 25% growth, driven by expanding adoption of the RNS System and disciplined execution. Strategic focus remains on core business growth, indication expansion, and leveraging proprietary data for AI-driven product development. Guidance for 2026 projects continued robust growth and margin improvement.
NeuroPace Reports Preliminary Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported preliminary unaudited ...
NeuroPace to Present at the 44th Annual J.P. Morgan Healthcare Conference
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Files PMA Supplement to FDA Seeking Expanded RNS® System Indication for Idiopathic Generalized Epilepsy
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that it has filed a P...
NeuroPace Announces Positive 18-Month NAUTILUS Trial Results in Idiopathic Generalized Epilepsy
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, announced the presentation at the Ame...
NeuroPace to Highlight Life-Changing Outcomes and AI-Powered Confident Care at the 2025 American Epilepsy Society (AES) Annual Meeting
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its RNS System a...
NeuroPace Announces Favorable Medicare Reimbursement Increases for RNS System Physician and Hospital Outpatient Services
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today announced favorable Medicar...
NeuroPace Earnings Call Transcript: Q3 2025
Record Q3 revenue and positive adjusted EBITDA were achieved, driven by strong RNS growth and broad-based adoption. Full-year guidance for revenue and gross margin was raised, with the RNS segment expected to sustain 20%+ growth as DIXI winds down.
NeuroPace Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today reported financial results for ...
NeuroPace to Report Third Quarter 2025 Financial Results on November 4, 2025
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced it will report financ...
NeuroPace Transcript: Cantor Global Healthcare Conference 2025
The company is expanding access to its responsive neurostimulation device for drug-resistant epilepsy, leveraging regulatory approvals, data-driven insights, and partnerships to address unmet needs. Clinical trials support indication expansion, and strong financial growth is projected.
NeuroPace to Participate in Upcoming Healthcare Conferences
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management t...
NeuroPace Earnings Call Transcript: Q2 2025
Record Q2 revenue and gross margin led to raised full-year guidance. RNS System growth, Project CARE expansion, and debt refinancing drove strong results, while Dixi Medical sales will phase out. NAUTILUS and pediatric markets offer future growth opportunities.
NeuroPace Reports Second Quarter 2025 Financial Results and Increases 2025 Revenue Guidance
-- Reported record quarterly revenue of $23.5 million in Q2 2025-- -- Increased full-year 2025 revenue guidance to between $94 million and $98 million and gross margin guidance to between 75% and 76%-...
NeuroPace Commends CMS for Maintaining FY25 Reimbursement Structure for Epilepsy with Neurostimulator Cases
MOUNTAIN VIEW, Calif., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical technology company focused on transforming the lives of people living with epilepsy, today issued the...
NeuroPace Announces Strategic CFO Transition
Appoints Patrick F. Williams as Chief Financial Officer Williams Brings a Track Record of Leading Medical Device Public Companies as CFO Rebecca Kuhn Departing Company and Will Remain in Advisory Role...
NPCE Investors Have Opportunity to Join NeuroPace, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES , June 24, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of NeuroPace, Inc. ("Ne...